Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Q2 2026 · $65.5MThe company’s own SEC segment disclosure.
- Material Sales Captisol$8.0M12%
- Contract Revenue And Income$7.7M12%
- Contract Revenue And Other Income$7.7M12%
- Kyprolis$7.0M11%
- QARZIBA$6.2M9%
- Contract And Revenue Income Other$5.0M8%
- Other (9)$24.0M37%
Ligand Pharmaceuticals Incorporated (LGND) reported revenue of $64M in Q2 2026 (quarter ended Jun 30, 2026), up 34% from the same quarter a year earlier. That came with net income of $49M (76% of revenue). For the full year FY2025, revenue was $268M (+60% year on year) and net income $124M. Its largest product in Q2 2026 was Material Sales Captisol at $8.0M, 12.2% of the disclosed total, just ahead of Contract Revenue And Income at 11.7%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.